Illumina

As Diwali begins, Illumina celebrates new beginnings and global momentum. From Bengaluru to San Diego, our teams are energized for what’s ahead. Full story ➡️ https://lnkd.in/g6ZDqiva

Thank you to our customers, collaborators, and greater scientific community for an inspiring #ASHG25. The future of sequencing is collaborative, connected, and multiomic. What was your favorite moment from this week?

The future of discovery is multiomic. At #ASHG25, we're demonstrating how innovations like Illumina Protein Prep and Single Cell are connecting data across the omes with NGS-level precision, flexibibility, scale, and insights that go beyond the sequencer. 🎥 Cande Rogert, PhD, VP, Global Head of Advanced Science at Illumina and Brendan Keating, PhD, Associate Professor at NYU Langone Health, share how Illumina is leading the way in multiomics and redefining how discovery happens.

We’re at #ASHG25 showcasing how Illumina is redefining what’s possible in sequencing. Constellation mapped read technology and the newly launched 5-base solution are giving researchers a more complete view of the genome, helping partners like GeneDx drive transformative omics innovations. Hear from Steven Barnard, PhD, CTO at Illumina, and Joseph Devaney, PhD, Director of Laboratory Innovation Team at GeneDx, on how Illumina is pushing the boundaries of discovery and shaping the next era of genomics. ⬇️

We’ve spent years pushing the limits of what short-read sequencing can do. Now, with our emerging constellation mapped read technology, we’re breaking new barriers and enabling the industry to uncover even deeper insights from the genome. GeneDx recently piloted constellation to evaluate its performance in the most challenging genomic regions. Early results illustrate its ability to rapidly identify hard-to-detect variants implicated in rare disease, like DMPK, SMN1, and mosaic aneuploidy. Joseph Devaney, Director of the Laboratory Innovation Team at GeneDx, said: “We’re continually looking to advance research and clinical genomics to drive the future of precision medicine and better health outcomes for all. The level of detail we can achieve with Constellation provides promising insight into some of the world’s most complex and difficult-to-diagnose diseases.” Constellation delivers long-range genomic insights with a simplified, on-flow-cell library prep that removes manual steps — all within the workflows our customers know and trust. 📍GeneDx presented the results of their pilot today at #ASHG25. Read more here: https://bit.ly/4oaVLkh

The wait is over: the Illumina 5-Base solution is here. Now you can simultaneously detect methylation and genomic variants in one streamlined workflow, delivering comprehensive insights without compromising quality or library diversity. ✅ Simplify your process – one integrated workflow reduces complexity ✅ Boost efficiency – save time and resources with a single assay with dual insights ✅ Ensure confidence – get accurate combined methylation and variant data Reimagine your workflow: https://bit.ly/45x6BZB

We’re here at #ASHG25 and ready to share how our latest innovations are shaping the next wave of biology. From scalable single-omic to fully multiomic workflows, we’re empowering researchers to unlock every assay, every variant, every layer of biology from genome to proteome. Visit us at booth 1019 and don't miss our industry education and CoLab sessions. Register for the on-demand webinar: https://bit.ly/4o7OHo1

We conducted a new internal benchmarking study that compared the NovaSeq™ X Series to Ultima Genomics’ UG 100 platform. The data are clear: NovaSeq X delivers greater accuracy, coverage, and biologically relevant insights across the entire genome when assessed against the full NIST v4.2.1 benchmark.  📉 6× fewer SNV errors and 22× fewer indel errors  📈 ~450,000 additional variants detected by analyzing the entire benchmark, not a limited subset (Ultima Genomics’ high confidence region “HCR”)  💪 Stronger performance in GC-rich and repetitive regions, often associated with disease biology  🎯 Greater accuracy across biologically relevant genes such as BRCA1, B3GALT6, and FMR1 Click here for the full study: https://lnkd.in/gbRhEtHQ  

Over the last 20 years, Illumina sequencing-by-synthesis (SBS) technology has transformed genome sequencing, leading a new era of high accuracy genomics at scale. Yet, some regions of the genome remain challenging. The new Illumina constellation mapped read technology is changing that. This emerging technology will simplify the NGS workflow with on-flow-cell library prep, unlocking long-range genomic information to power new insights. It can resolve tricky regions, enable ultra-long phasing of genetic variants, and enhance detection of structural variants. See our mapped read technology in action at #ASHG25, and learn how it’s shaping the future of genome sequencing: https://bit.ly/4pZX6LX

Bekim Sadikovic, Director of the Molecular Genetics Laboratory at London Health Sciences Centre Research Institute (LHSCRI), is dedicated to finding new ways to interrogate multiomic questions around rare disease.   With early access to the Illumina 5-base solution, his team was able to generate combined genomic and epigenomic data in a single workflow, revealing regulatory mechanisms in rare disease research that sequencing alone could not capture.   Join Bekim at #ASHG25 on October 15, 12:00–1:00 PM EST in Room 153 ABC to hear more: https://lnkd.in/dC2DMFjR